Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Deferred Taxes (2016 - 2019)

Historic Deferred Taxes for Harvard Bioscience (HBIO) over the last 11 years, with Q3 2019 value amounting to $42000.0.

  • Harvard Bioscience's Deferred Taxes fell 7407.41% to $42000.0 in Q3 2019 from the same period last year, while for Sep 2019 it was -$2.9 million, marking a year-over-year decrease of 9011.86%. This contributed to the annual value of -$2.9 million for FY2018, which is 8061.87% down from last year.
  • Latest data reveals that Harvard Bioscience reported Deferred Taxes of $42000.0 as of Q3 2019, which was down 7407.41% from -$1000.0 recorded in Q1 2019.
  • Harvard Bioscience's 5-year Deferred Taxes high stood at $16.1 million for Q4 2015, and its period low was -$2.9 million during Q4 2018.
  • Over the past 5 years, Harvard Bioscience's median Deferred Taxes value was $1000.0 (recorded in 2015), while the average stood at $745214.3.
  • Per our database at Business Quant, Harvard Bioscience's Deferred Taxes plummeted by 101904.76% in 2015 and then soared by 1493333.33% in 2016.
  • Over the past 5 years, Harvard Bioscience's Deferred Taxes (Quarter) stood at $16.1 million in 2015, then tumbled by 104.55% to -$734000.0 in 2016, then plummeted by 115.8% to -$1.6 million in 2017, then plummeted by 84.79% to -$2.9 million in 2018, then surged by 101.43% to $42000.0 in 2019.
  • Its Deferred Taxes stands at $42000.0 for Q3 2019, versus -$1000.0 for Q1 2019 and -$2.9 million for Q4 2018.